Infectious Vaccine Collaboration and Licensing Agreements Analysis Report 2025 with Directory of 543 Deals Signed Since 2016 - Access Upfront, Milestone, Royalties Data - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Infectious Vaccine Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 543 infectious vaccine deals announced since 2016 including financial terms where available including links to online deal records of actual infectious vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2025, the report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

The initial chapters of this report provide an orientation of infectious vaccine dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in infectious vaccine dealmaking since 2016.

Chapter 3 provides an overview of the leading infectious vaccine deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in infectious vaccine dealmaking with a brief summary followed by a comprehensive listing of infectious vaccine deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of infectious vaccine deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of infectious vaccine partnering deals signed and announced since Jan 2016. The chapter is organized by specific infectious vaccine technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in infectious vaccine deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Infectious Vaccine Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse infectious vaccine collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious vaccine dealmaking

2.1. Introduction

2.2. Infectious vaccine deals over the years

2.3. Most active infectious vaccine dealmakers

2.4. Infectious vaccine deals by deal type

2.5. Infectious vaccine deals by therapy area

2.6. Infectious vaccine deals by industry sector

2.7. Deal terms for infectious vaccine deals

2.7.1 Infectious vaccine deals headline values

2.7.2 Infectious vaccine deal upfront payments

2.7.3 Infectious vaccine deal milestone payments

2.7.4 Infectious vaccine royalty rates

Chapter 3 - Leading infectious vaccine deals

3.1. Introduction

3.2. Top infectious vaccine deals by value

Chapter 4 - Most active infectious vaccine dealmakers

4.1. Introduction

4.2. Most active infectious vaccine dealmakers

4.3. Most active infectious vaccine deals company profiles

Chapter 5 - Infectious vaccine contracts dealmaking directory

5.1. Introduction

5.2. Infectious vaccine contracts dealmaking directory

Chapter 6 - Infectious vaccine dealmaking by technology type

Deal directory

• Infectious Vaccine Deals by Company A-Z
• Infectious Vaccine Deals by Deal Type
• Infectious Vaccine Deals by Therapy Area

For more information about this report visit https://www.researchandmarkets.com/r/wwsf5e

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.